Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study Save

Date Added
October 15th, 2019
PRO Number
Pro00093504
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer/Gastrointestinal
Summary

This study is for older adults with colorectal cancer. The purpose is to determine if low muscle mass plays a role in side effects from chemotherapy.

Institution
MUSC
Recruitment Contact
Nancy McGaha
864-725-7129
nmcgaha@selfregional.org

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Save

Date Added
August 28th, 2019
PRO Number
Pro00086110
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies
Summary

This is a research study to compare the effects and safety, good or bad, of tislelizumab (also known as BGB-A317) plus chemotherapy against placebo (an inactive substance) plus chemotherapy for adults with locally advanced recurrent or metastatic esophageal squamous cell carcinoma to find out which is better. Subjects may continue study treatment during their participation in the study as long as there is no worsening of disease and they don't have intolerable side effects from the study treatment

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clincal-trials@musc.edu

A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors Save

Date Added
August 13th, 2019
PRO Number
Pro00090771
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies
Summary

The purpose of this study is to explore any changes in tumors after adult subjects (ages 18+) who have advanced pancreatic or colorectal cancer receive an immunotherapy drug, called BMS-813160, alone or together with another immunotherapy drug, called nivolumab or chemotherapy. BMS-813160 and nivolumab belongs to a class of drugs called immunotherapies. ?Immuno' in ?immunotherapy' refers to the immune system. The immune system is the body's natural defense against illnesses like colds, infections, and cancer. There is no defined length of time for this study. The exact time commitment will depend on several factors, such as availability to come for appointments, cancer's response to the study drugs, reaction to the study drugs, and the sponsor's decision of whether to continue the study.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9300
hcc-clinical-trials@musc.edu

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab Save

Date Added
February 26th, 2019
PRO Number
Pro00086647
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer, Cancer/Skin
Summary

This study is for patients that have been diagnosed with Merkle Cell Carcinoma. The investigational drug in this study is pembrolizumab. The purpose of this study is to compare the usual approach of post-surgery observation with or without radiation to using pembrolizumab with or without radiation after surgery. Participants can expect to be on this study for a total of 5 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1 Save

Date Added
November 30th, 2018
PRO Number
Pro00079574
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies
Summary

The purpose of this study is to evaluate the safety and effectiveness of a new investigational compound, called FPA144, in combination with chemotherapy (a combination of 5-fluorouracil, oxaliplatin, and leucovorin called mFOLFOX6), for the treatment of gastric and/or gastroesophageal cancer and other solid tumors. The entire study (Phase 1 and Phase 3) is expected to take about 66 months to complete. MUSC is participating in the phase 3 portion only.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clincal-trials@musc.edu

A Randomized Phase II Study of Anti-PD1 Antibody (MK-3475 (Pembrolizumab)) Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma Save

Date Added
August 9th, 2018
PRO Number
Pro00080885
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer, Cancer/Skin
Summary

This study is for patients that have been diagnosed with Merkel cell carcinoma. The investigational drug in this study is pembrolizumab. This study will compare any good and bad effects of using radiation along with an immunotherapy treatment [MK-3475 (pembrolizumab)] compared with MK-3475 (pembrolizumab) alone. Participants can expect to be in this study for up to 7 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer Save

Date Added
March 27th, 2018
PRO Number
Pro00075360
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies, Pancreas
Summary

This study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer. There is not a set number of clinic visits and subjects can remain on study provided their disease is at least stable for each imaging time point, and if study drugs are sufficiently tolerated

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login